Biotechnology company Dermata Therapeutics, developing drugs for the treatment of skin diseases based on badyagi in 3 research phase, attracted 18 million dollars, releasing 2,6 million packages of 7 dollars - the minimum price of the stated range from 7 to 9 Dollars. The company offered at 0,7 million packages more, than planned. Each package includes an ordinary share and one order, exchangeable by 7 Dollars.
Dermata specializes in the treatment of medical and aesthetic skin problems based on its proprietary high-tech platform Spongilla, based on the use of wild spongilla lacustris. DMT310 Lead Candidate is a once-a-week product, which is currently in clinical research for the treatment of acne, psoriasis and rosacea. The company recently received results from a Phase 2b study of DMT310 for the treatment of moderate to severe acne., and in 2 Half 2022 year plans to start phase 3 two pivotal studies, results are expected in 1 Half 2024 of the year.
Dermata Therapeutics plans to list on the stock exchange Nasdaq under the ticker DRMA. Maxim Group LLC became the sole organizer of the share issue.
